Professor Lisa Bero

BSc, PhD
Professor, Faculty of Pharmacy
Chair, Medicines Use and Health Outcomes,
Faculty of Pharmacy and Charles Perkins Centre

D17 - Charles Perkins Centre
The University of Sydney

Telephone +61 2 8627 1881
Fax +61 2 9351 6950

Biographical details

Professor Lisa Bero is a pharmacologist and researcher in evidence-based health care who is internationally renowned for her studies on the integrity of clinical and basic research evidence that is used to influence health policy, and the manner in which evidence is communicated to key groups such as physicians, policy-makers, journalists and the community. She leads the Bias and Research Integrity Node at the Charles Perkins Centre. Prior to joining the University of Sydney in 2014, she was Professor at the Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California San Francisco (UCSF). Professor Bero is recognised for her methodological studies on bias (including publication/reporting, design and funding biases) in the fields of clinical medicine (pharmaceuticals), tobacco control and environmental research, and on the use and implications of the evidence for prescribing decisions/policy. Her expertise lies in investigating hidden biases in the design, conduct and publication of research, and includes ground-breaking work that demonstrated the selective reporting of data for drugs approved by the FDA (PLoS Medicine 2008) and a paper (BMJ 2012) which showed that including unpublished outcomes of drug studies in meta-analyses changes the results of all relevant meta-analyses. These findings have contributed to open access data reforms such as access to information from drug regulatory agencies and improved reporting requirements for clinical trials on the clinicaltrials.gov registry. Additionally her interest in evidence-based policy led to work examining influences on the production and dissemination of science. At the University of Sydney, she directs a multidisciplinary team analysing research quality (initially in nutrition research). She notes, “the overall objective is to improve the conduct and reporting standards of research and facilitate the development of sound evidence-based health policy that will help reduce the burden of obesity, cardiovascular disease and diabetes”. Professor Bero’s interest in medicines use in low-resource settings has seen her work extensively with the WHO as Chair of its Essential Medicines Committee, helping assess research submissions for categorisation of essential medicines.

Professor Bero is Director of the WHO Collaborating Centre on Pharmaceutical Research and Science Policy, member of the Pan American Health Organization Advisory Committee on Health Research, and co-Chair of the Cochrane Collaboration. She received the Cochrane Collaboration’s 2013 Bill Silverman Prize for her published cross-sectional study (BMJ 2012) on the reporting of conflicts of interest from drug trials in Cochrane reviews.

Research interests

Professor Bero’s overall research program addresses the broad questions regarding research evidence including: What is evidence? How can we reduce bias in the evidence base, specifically the design, conduct and reporting of research? How can we communicate research findings in an understandable and convincing way to a variety of stakeholders? How can we promote the use of evidence in decision making while taking into account the social, political and ethical context of decisions?

Her planned current and future work includes methodological analyses of nutrition research relevant to the treatment and prevention of obesity, diabetes and cardiovascular disease and promoting the use of quality evidence to inform health policy to reduce the burden of these diseases. Her research program will focus on describing cultural, social, corporate, political and other influences on the design, conduct and publication of research. An additional program will focus on improving medicines use for noncommunicable diseases in low-resource settings. Her team will study the process of innovation for medicines for noncommunicable disease, assess barriers and facilitators to the quality use of essential medicines, and develop and test interventions to improve essential medicines policy, supply, distribution and use.

Further proposed research includes analyses of the results and biases in preclinical animal studies, as these studies are critical for evaluating the efficacy and safety of drugs before proceeding to human testing. The aim is to provide an internationally-applicable evidence base for developing strategies and policies for controlling bias in preclinical animal research. Future research will explore ways to improve the assessment of the risk of bias in clinical trials of high-cost new cancer therapeutics, and studies on the impact of unpublished data on the cost-effectiveness of medicines.

Teaching and supervision

Critical appraisal of the medical literature, meta-analysis and systematic reviews.

2015 Summer Scholarship Project

Associations

The Cochrane Collaboration (co-Chair)

Awards and honours

2003

Author of most cited paper in Public Money and Management

2004

Author of most cited paper in Tobacco Control for 3 months

2009

HaroldS. Luft Award for Mentoring in Health Services and Health Policy Research

2009

UCSF Distinction in Mentoring Award

2009

Research Preceptor for Gary Rifkind Spring Research Seminar Award to Luke Tso for Student Pharmacist Exposure and Attitudes towards Pharmaceutical Company Marketing Practices"

2010

Research Preceptor for 2010 CHIH Foundation Research Award to Timothy Millar and Shirley Wong for "Comparison of the World Health Organization Essential Medicines List (EML) with United States Medicaid Preferred Drug Lists (PDLs)"

2011

Co-author for Gary Rifkind Spring Research Seminar Award to Donna Odierna (professional researcher/ assistant professor category) for "Arguments for and against the use of Systematic Reviews in Healthcare Decision Making: Cui Bono?"

2011

Research Preceptor for Gary Rifkind Spring Research Seminar Award to Angela Anson (student category) for "Prices, availability and affordability of the World Health Organization's Essential Medicines for children in Guatemala"

2013

Honorary Lectureship, McGill University, Montreal

Keywords

Evidence-based medicine; Meta-analysis; Bias; Research translation

PhD and master's project opportunities

Selected grants

2012

  • Searching for Unpublished Trials; Bero L; Cochrane Collaboration/Research Support.

2011

  • Measuring Design, Reporting and Funding Bias in Nonclinical Research; Bero L; National Institute of Environmental Health Sciences (USA)/Research Grant.

2010

  • Conflict of Interest in Clinical Practice Guideline Development; Bero L; AHRQ/Project grant.

2007

  • Implementing the Evidence; Bero L; Flight Attendants Medical Research Institute/Research Grant.

2006

  • Development and Evaluation of a Curriculum for Improving Prescribing Practices; Bero L; Attorney General Prescribing Grant Program/Research Grant.

2005

  • Public Attitudes about Financial Ties of Researchers; Bero L; National Science Foundation/Research Grant.

2004

  • Corporate Strategies: Design, Conduct and Publication of Research; Bero L; Tobacco Related Disease Research Program/Research Grant.

2003

  • Development of Smoking Restrictions on Airlines; Bero L; Flight Attendants Medical Research Institute/Research Grant.

2002

  • Development and Implementation of Smoking Restriction Policies; Bero L; Flight Attendants Medical Research Institute/Research Grant.
  • Qualitative Study of Editorial Decision-Making; Bero L; National Institutes of Health (USA)/Research Grant.

2001

  • Management Decisions in Financial Conflicts of Interest; Bero L; National Institutes of Health (USA)/Research Grant.

2000

  • Analysis of Tobacco Industry Document on Scientific Research; Bero L; California Tobacco-Related Disease Research Program/Research Grant.

1998

  • Development of a Faculty Financial Disclosure Database; Bero L; Industry-University Cooperative Research Program/Research Grant.
  • Implementation of California AB13: Smoking Ban in Bars; Bero L; California Tobacco-Related Disease Research Program/Research Grant.

1997

  • Roles of Media and Community Response in the Recent Cigar Trend; Bero L; California Tobacco-Related Disease Research Program/Research Grant.
  • Developing Policy to Reverse the Cigar Trend; Bero L; National Institutes of Health (USA)/Research Grant.
  • Improving the Use of Research for Policy: Case Studies in Tobacco Control; Bero L; American Cancer Society/Research Grant.
  • Case Studies of Indoor Air Regulation: Role of Research; Bero L; California Tobacco-Related Disease Research Program/Research Grant.

1994

  • Use of Tobacco Industry-Sponsored Research to Influence Policy; Bero L; The Robert Wood Johnson Foundation/Investigator Award.

1993

  • Quality of Drug Studies; Bero L; American Association of Retired Persons/Research Award.
  • Citation of Tobacco Industry-Sponsored Symposia Study; Bero L; National Cancer Institute (USA)/Contract.
  • Quality of Tobacco Industry-Funded Research; Bero L; California Tobacco-Related Disease Research Program/Research Grant.
  • Citation Analysis; Bero L; Kaiser Family Foundation/Grant.

1992

  • Evaluation of the Mandatory Patient Consultation Regulation; Bero L; Amgen, Inc./Grant.

1991

  • Pharmaceutical Industry Sponsored Symposia Study; Bero L; American Association of Retired Persons/Research Award.
  • The Tobacco Industry and Scientific Research; Bero L; California Tobacco-Related Disease Research Program/Career Development Award.

1988

  • Fellowship in Health Policy; Bero L; Pew/Fellowship.

1987

  • National Institute on Drug Abuse Individual National Research Service Award; Bero L; University of California, San Francisco/Research Service Award.

Selected publications & creative works

Download citations: PDF RTF Endnote

Book Chapters

  • Bero, L. (2013). Tobacco industry manipulation of research. In David Gee, Philippe Grandjean, Steffen Foss Hansen, Sybille van den Hove, et al (Eds.), Late lessons from early warnings: science, precaution, innovation, (pp. 151-178). Copenhagen: European Environmental Agency.

Journals

  • Alexander, P., Gionfriddo, M., Li, S., Bero, L., Stoltzfus, R., Neumann, I., Brito, J., Djulbegovic, B., Montori, V., Norris, S., et al (2016). A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 70, 111-122. [More Information]
  • Alexander, P., Brito, J., Neumann, I., Gionfriddo, M., Bero, L., Djulbegovic, B., Stoltzfus, R., Montori, V., Norris, S., Schunemann, H., et al (2016). World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 72, 98-106. [More Information]
  • Chiu, Y., Bero, L., Hessol, N., Lexchin, J., Harrington, C. (2015). A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy, 119(6), 802-813. [More Information]
  • Tran, D., Bero, L. (2015). Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. Journal of Global Health, 5(1), 1-9. [More Information]
  • Tuller, D., Bero, L. (2015). Big Tobacco and Drugstore Chains: A Long, Cozy Relationship. JAMA Oncology, 1(9), 1215-1216. [More Information]
  • Hill, S., Bero, L., McColl, G., Roughead, E. (2015). Expensive medicines: ensuring objective appraisal and equitable access. Bulletin of the World Health Organization, 93(1), 4-4A. [More Information]
  • Anglemyer, A., Krauth, D., Bero, L. (2015). Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: A meta-analysis. BMC Medical Research Methodology, 15(1), 1-10. [More Information]
  • Elliott, J., Grimshaw, J., Altman, R., Bero, L., Goodman, S., Henry, D., Macleod, M., Tovey, D., Tugwell, P., White, H., et al (2015). Informatics: Make sense of health data. Nature, 527(7576), 31-32. [More Information]
  • Siler, K., Lee, K., Bero, L. (2015). Measuring the effectiveness of scientific gatekeeping. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(2), 360-365. [More Information]
  • Moynihan, R., Nickel, B., Hersch, J., Beller, E., Doust, J., Compton, S., Barratt, A., Bero, L., McCaffery, K. (2015). Public Opinions about Overdiagnosis: A National Community Survey. PloS One, 10(5), 1-13. [More Information]
  • Bero, L., Siler, K., Lee, K. (2015). Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(13), E1512-E1512. [More Information]
  • Chang, L., Dhruva, S., Chu, J., Bero, L., Redberg, R. (2015). Selective reporting in trials of high risk cardiovascular devices: Cross sectional comparison between premarket approval summaries and published reports. BMJ, 350, 1-7. [More Information]
  • Mahady, S., Schlub, T., Bero, L., Moher, D., Tovey, D., George, J., Craig, J. (2015). Side effects are incompletely reported among systematic reviews in gastroenterology. Journal of Clinical Epidemiology, 68(2), 144-153. [More Information]
  • Schroll, J., Abdel-Sattar, M., Bero, L. (2015). The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. Journal of Clinical Epidemiology, 68(1), 102-107. [More Information]
  • Abdel-Sattar, M., Krauth, D., Anglemyer, A., Bero, L. (2015). The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis. Evidence-based Preclinical Medicine, 1(1), 11-20. [More Information]
  • Bero, L. (2014). Bias related to funding source in statin trials. BMJ, 349, 1-2. [More Information]
  • Forsyth, S., Odierna, D., Krauth, D., Bero, L. (2014). Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles. Systematic Reviews, 3(1), 1-11. [More Information]
  • Anglemyer, A., Horvath, H., Bero, L. (2014). Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database of Systematic Reviews, 4(2014), 1-44. [More Information]
  • Krauth, D., Anglemyer, A., Philipps, R., Bero, L. (2014). Nonindustry-Sponsored Preclinical Studies on Statins Yield Greater Efficacy Estimates Than Industry-Sponsored Studies: A Meta-Analysis. PLoS Biology, 12(1), 1-10. [More Information]
  • Magrini, N., Robertson, J., de Joncheere, K., Bero, L. (2014). On WHO's essential medicines process and transparency. BMJ, 349, 1-1. [More Information]
  • Coralic, Z., Kanzaria, H., Bero, L., Stein, J. (2014). Staff Perceptions of an On-site Clinical Pharmacist Program in an Academic Emergency Department after One Year. Western Journal of Emergency Medicine, 15(2), 205-210. [More Information]
  • Apollonio, D., Glantz, S., Bero, L. (2014). Term limits and the tobacco industry. Social Science and Medicine, 104(2014), 1-5. [More Information]
  • Bero, L. (2014). What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. Journal of Clinical Epidemiology, 67(11), 1239-1241. [More Information]
  • Alexander, P., Bero, L., Montori, V., Brito, J., Stoltzfus, R., Djulbegovic, B., Neumann, I., Rave, S., Guyatt, G. (2014). World Health Organization recommendations are often strong based on low confidence in effect estimates. Journal of Clinical Epidemiology, 67(6), 629-634. [More Information]
  • Chahal, H., St. Fort, N., Bero, L. (2013). Availability, prices and affordability of essential medicines in Haiti. Journal of Global Health, 3(2), 1-11. [More Information]
  • Moynihan, R., Cooke, G., Doust, J., Bero, L., Hill, S., Glasziou, P. (2013). Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States. PLoS Medicine, 10(8), 1-12. [More Information]
  • Krauth, D., Woodruff, T., Bero, L. (2013). Instruments for Assessing Risk of Bias and Other Methodological Criteria of Published Animal Studies: A Systematic Review. Environmental Health Perspectives, 121(9), 985-992. [More Information]
  • Grundy, Q., Bero, L., Malone, R. (2013). Interactions between Non-Physician Clinicians and Industry: A Systematic Review. PLoS Medicine, 10(11), 1-13. [More Information]
  • Nguyen, N., Bero, L. (2013). Medicaid Drug Selection Committees and Inadequate Management of Conflicts of Interest. JAMA Internal Medicine, 173(5), 338-343. [More Information]
  • Conway, J., Bero, L., Ondari, C., Wasan, K. (2013). Review of the Quality of Pediatric Medications in Developing Countries. Journal of Pharmaceutical Sciences, 102(5), 1419-1433. [More Information]
  • Schroll, J., Bero, L., Gøtzsche, P. (2013). Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ, 346(7913), 1-11. [More Information]
  • Wolfe, N., Gøtzsche, P., Bero, L. (2013). Strategies for obtaining unpublished drug trial data: a qualitative interview study. Systematic Reviews, 2, 1-11. [More Information]
  • Odierna, D., Forsyth, S., White, J., Bero, L. (2013). The Cycle of Bias in Health Research: A Framework and Toolbox for Critical Appraisal Training. Accountability in Research: policies and quality assurance, 20(2), 127-141. [More Information]
  • Pande, S., Hiller, J., Nkansah, N., Bero, L. (2013). The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database of Systematic Reviews, 2, 1-72. [More Information]
  • Bero, L., Hill, S., Habicht, J., Mathiesen, M., Starkopf, J. (2013). The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. Journal of Clinical Epidemiology, 66(2), 132-139. [More Information]
  • Norris, S., Burda, B., Holmer, H., Ogden, L., Fu, R., Bero, L., Schünemann, H., Deyo, R. (2012). Author’s specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. Journal of Clinical Epidemiology, 65(7), 725-733. [More Information]
  • Anson, A., Ramay, B., de Esparza, A., Bero, L. (2012). Availability, prices and affordability of the World Health Organization’s essential medicines for children in Guatemala. Globalization and Health, 8, 1-10. [More Information]
  • Taba, P., Rosenthal, M., Habicht, J., Tarien, H., Mathiesen, M., Hill, S., Bero, L. (2012). Barriers and facilitators to the implementation of clinical practice guidelines: A cross-sectional survey among physicians in Estonia. BMC Health Services Research, 12(1), 1-7. [More Information]
  • Hart, B., Lundh, A., Bero, L. (2012). Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ, 344(7838), 1-11. [More Information]
  • Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O., Bero, L. (2012). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 12(2012), 1-88. [More Information]
  • Hill, S., Yang, A., Bero, L. (2012). Priority Medicines for Maternal and Child Health: A Global Survey of National Essential Medicines Lists. PloS One, 7(5), 1-6. [More Information]
  • Roseman, M., Turner, E., Lexchin, J., Coyne, J., Bero, L., Thombs, B. (2012). Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ, 345, 1-10. [More Information]
  • Malone, R., Grundy, Q., Bero, L. (2012). Tobacco industry denormalisation as a tobacco control intervention: a review. Tobacco Control, 21(2), 162-170. [More Information]
  • Woodruff, T., Sutton, P., Cogliano, V., Guyton, K., Quint, J., Zeise, L., Balk, J., Bero, L., Conry, J., Fox, D., et al (2011). An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences. Health Affairs, 30(5), 931-937. [More Information]
  • Millar, T., Wong, S., Odierna, D., Bero, L. (2011). Applying the Essential Medicines Concept to US Preferred Drug Lists. American Journal of Public Health, 101(8), 1444-1448. [More Information]
  • Walleser, S., Hill, S., Bero, L. (2011). Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. Journal of Clinical Epidemiology, 64(12), 1331-1340. [More Information]
  • Dhruva, S., Bero, L., Redberg, R. (2011). Gender Bias in Studies for Food and Drug Administration Premarket Approval of Cardiovascular Devices. Circulation. Cardiovascular Quality and Outcomes, 4(2), 165-171. [More Information]
  • Chen, C., Dhruva, S., Bero, L., Redberg, R. (2011). Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies. Archives of Internal Medicine, 171(6), 534-539. [More Information]
  • Krleža-Jeriç, K., Lemmens, T., Reveiz, L., Cuervo, L., Bero, L. (2011). Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Revista Panamericana de Salud Publica-Pan (American Journal of Public Health), 30(1), 87-96.
  • Roseman, M., Milette, K., Bero, L., Coyne, J., Lexchin, J., Turner, E., Thombs, B. (2011). Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA: The Journal of the American Medical Association, 305(10), 1008-1017. [More Information]
  • White, J., Bero, L. (2010). Corporate manipulation of research: Strategies are similar across five industries. Stanford Law and Policy Review, 21(1), 105-134.
  • Smith, M., Bero, L., Carber, L. (2010). Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors. Chiropractic and Osteopathy, 18(2010), 1-8. [More Information]
  • Nkansah, N., Mostovetsky, O., Yu, C., Chheng, T., Beney, J., Bond, C., Bero, L. (2010). Effect of outpatient pharmacists’ non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database of Systematic Reviews, 7(2010). [More Information]
  • Ridge, A., Bero, L., Hill, S. (2010). Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: A case study in Zambia. BMC Health Services Research, 10, 1-9. [More Information]
  • Robertson, J., Walkom, E., Moynihan, R., Bero, L., Henry, D. (2010). Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. International Journal of Pharmacy Practice, 18(2), 88-92. [More Information]
  • Montini, T., George, A., Martin-Mollard, M., Bero, L. (2010). The role of public participation in public health initiatives: An analysis of the WHO Framework Convention on Tobacco Control. Global Public Health, 5(1), 48-61. [More Information]
  • Bero, L., Carson, B., Moller, H., Hill, S. (2010). To give is better than to receive: compliance with WHO guidelines for drug donations during 2000–2008. Bulletin of the World Health Organization, 88(12), 922-929. [More Information]
  • Cataldo, J., Bero, L., Malone, R. (2010). ‘‘A delicate diplomatic situation’’: tobacco industry efforts to gain control of the Framingham Study. Journal of Clinical Epidemiology, 63(8), 841-853. [More Information]
  • Apollonio, D., Bero, L. (2009). Evidence and argument in policymaking: development of workplace smoking legislation. BMC Public Health, 9, 1-10. [More Information]
  • Rattinger, G., Bero, L. (2009). Factors Associated with Results and Conclusions of Trials of Thiazolidinediones. PloS One, 4(6), 1-10. [More Information]
  • Cook, D., Boyd, E., Grossman, C., Bero, L. (2009). Journalists and conflicts of interest in science: Beliefs and practices. Ethics in Science and Environmental Politics, 9(1), 33-40. [More Information]
  • Robertson, J., Moynihan, R., Walkom, E., Bero, L., Henry, D. (2009). Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals. PLoS Medicine, 6(11), 1-5. [More Information]
  • White, J., Bandura, A., Bero, L. (2009). Moral disengagement in the corporate world. Accountability in Research: policies and quality assurance, 16(1), 41-74. [More Information]
  • Vedula, S., Bero, L., Scherer, R., Dickersin, K. (2009). Outcome Reporting in Industry-Sponsored Trials Of Gabapentin for Off-Label Use. The New England Journal of Medicine, 361(20), 1963-1971. [More Information]
  • Kummerfeldt, C., Barnoya, J., Bero, L. (2009). Philip Morris involvement in the development of an air quality laboratory in El Salvador. Tobacco Control, 18(3), 241-244. [More Information]
  • Nkansah, N., Nguyen, T., Iraninezhad, H., Bero, L. (2009). Randomized trials assessing calcium supplementation in healthy children: Relationship between industry sponsorship and study outcomes. Public Health Nutrition, 12(10), 1931-1937. [More Information]
  • Cook, D., Gurugubelli, R., Bero, L. (2009). Risk Management Policy and Black-Box Warnings: A Qualitative Analysis of US FDA Proceedings. Drug Safety, 32(11), 1057-1066. [More Information]
  • Dhruva, S., Bero, L., Redberg, R. (2009). Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices. JAMA: The Journal of the American Medical Association, 302(24), 2679-2685. [More Information]
  • Odierna, D., Bero, L. (2009). Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. Journal of Clinical Epidemiology, 62(12), 1268-1278. [More Information]
  • Cook, D., Bero, L. (2009). The Politics of Smoking in Federal Buildings: An Executive Order Case Study. American Journal of Public Health, 99(9), 1588-1595. [More Information]

Conferences

  • Bero, L. (2012). Assessing Risk of Bias. Australian Pharmaceutical Benefits Advisory Committee's April Meeting.
  • Bero, L. (2012). Selective outcome reporting: Impact on Drug Evaluation. Australian Pharmaceutical Benefits Advisory Committee's April Meeting.
  • Bero, L. (2011). Ghosts, guests and other distortions of authorship in medical and scientific journals. COPE (Committee on Publication Ethics) North American Seminar and Forum, San Diego, North America.
  • Bero, L. (2011). The Cochrane Collaboration and Clinical Practice Guidelines. Estonian Health Insurance Fund and World Health Organization. Tallin, Estonia (September 7).
  • Bero, L. (2010). Evidence: Can we Trust it? Evidence on trial: has it made an impact on health?.
  • Bero, L. (2010). International ethical guidelines regarding inclusion of children in clinical trials. StaR Child Health Conference.
  • Bero, L. (2010). Taming the beast: managing conflicts of interest in research. World Health Organisation Conference.
  • Rasmussen, N., Lee, K., Bero, L. (2009). Association of trial registration with the results and conclusions of published trials of new oncology drugs. 6th International Congress on Peer Review and Biomedical Publication 2009, Vancouver, British Columbia, Canada. [More Information]
  • Bero, L. (2009). Tainted evidence on drugs. International Cochrane Symposium. Evidence-based Medicine and Systematic Reviews: Challenges and Opportunities.

Research Reports

  • Van den Ham, R., Bero, L., Laing, R. (2011). The world medicines situation report 2011: Selection of Essential Medicines, WHO/EMP/MIE/2011.2.8, (pp. 1 - 18). Geneva, Switzerland: World Health Organisation.

2016

  • Alexander, P., Gionfriddo, M., Li, S., Bero, L., Stoltzfus, R., Neumann, I., Brito, J., Djulbegovic, B., Montori, V., Norris, S., et al (2016). A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 70, 111-122. [More Information]
  • Alexander, P., Brito, J., Neumann, I., Gionfriddo, M., Bero, L., Djulbegovic, B., Stoltzfus, R., Montori, V., Norris, S., Schunemann, H., et al (2016). World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 72, 98-106. [More Information]

2015

  • Chiu, Y., Bero, L., Hessol, N., Lexchin, J., Harrington, C. (2015). A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy, 119(6), 802-813. [More Information]
  • Tran, D., Bero, L. (2015). Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. Journal of Global Health, 5(1), 1-9. [More Information]
  • Tuller, D., Bero, L. (2015). Big Tobacco and Drugstore Chains: A Long, Cozy Relationship. JAMA Oncology, 1(9), 1215-1216. [More Information]
  • Hill, S., Bero, L., McColl, G., Roughead, E. (2015). Expensive medicines: ensuring objective appraisal and equitable access. Bulletin of the World Health Organization, 93(1), 4-4A. [More Information]
  • Anglemyer, A., Krauth, D., Bero, L. (2015). Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: A meta-analysis. BMC Medical Research Methodology, 15(1), 1-10. [More Information]
  • Elliott, J., Grimshaw, J., Altman, R., Bero, L., Goodman, S., Henry, D., Macleod, M., Tovey, D., Tugwell, P., White, H., et al (2015). Informatics: Make sense of health data. Nature, 527(7576), 31-32. [More Information]
  • Siler, K., Lee, K., Bero, L. (2015). Measuring the effectiveness of scientific gatekeeping. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(2), 360-365. [More Information]
  • Moynihan, R., Nickel, B., Hersch, J., Beller, E., Doust, J., Compton, S., Barratt, A., Bero, L., McCaffery, K. (2015). Public Opinions about Overdiagnosis: A National Community Survey. PloS One, 10(5), 1-13. [More Information]
  • Bero, L., Siler, K., Lee, K. (2015). Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(13), E1512-E1512. [More Information]
  • Chang, L., Dhruva, S., Chu, J., Bero, L., Redberg, R. (2015). Selective reporting in trials of high risk cardiovascular devices: Cross sectional comparison between premarket approval summaries and published reports. BMJ, 350, 1-7. [More Information]
  • Mahady, S., Schlub, T., Bero, L., Moher, D., Tovey, D., George, J., Craig, J. (2015). Side effects are incompletely reported among systematic reviews in gastroenterology. Journal of Clinical Epidemiology, 68(2), 144-153. [More Information]
  • Schroll, J., Abdel-Sattar, M., Bero, L. (2015). The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. Journal of Clinical Epidemiology, 68(1), 102-107. [More Information]
  • Abdel-Sattar, M., Krauth, D., Anglemyer, A., Bero, L. (2015). The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis. Evidence-based Preclinical Medicine, 1(1), 11-20. [More Information]

2014

  • Bero, L. (2014). Bias related to funding source in statin trials. BMJ, 349, 1-2. [More Information]
  • Forsyth, S., Odierna, D., Krauth, D., Bero, L. (2014). Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles. Systematic Reviews, 3(1), 1-11. [More Information]
  • Anglemyer, A., Horvath, H., Bero, L. (2014). Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database of Systematic Reviews, 4(2014), 1-44. [More Information]
  • Krauth, D., Anglemyer, A., Philipps, R., Bero, L. (2014). Nonindustry-Sponsored Preclinical Studies on Statins Yield Greater Efficacy Estimates Than Industry-Sponsored Studies: A Meta-Analysis. PLoS Biology, 12(1), 1-10. [More Information]
  • Magrini, N., Robertson, J., de Joncheere, K., Bero, L. (2014). On WHO's essential medicines process and transparency. BMJ, 349, 1-1. [More Information]
  • Coralic, Z., Kanzaria, H., Bero, L., Stein, J. (2014). Staff Perceptions of an On-site Clinical Pharmacist Program in an Academic Emergency Department after One Year. Western Journal of Emergency Medicine, 15(2), 205-210. [More Information]
  • Apollonio, D., Glantz, S., Bero, L. (2014). Term limits and the tobacco industry. Social Science and Medicine, 104(2014), 1-5. [More Information]
  • Bero, L. (2014). What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. Journal of Clinical Epidemiology, 67(11), 1239-1241. [More Information]
  • Alexander, P., Bero, L., Montori, V., Brito, J., Stoltzfus, R., Djulbegovic, B., Neumann, I., Rave, S., Guyatt, G. (2014). World Health Organization recommendations are often strong based on low confidence in effect estimates. Journal of Clinical Epidemiology, 67(6), 629-634. [More Information]

2013

  • Chahal, H., St. Fort, N., Bero, L. (2013). Availability, prices and affordability of essential medicines in Haiti. Journal of Global Health, 3(2), 1-11. [More Information]
  • Moynihan, R., Cooke, G., Doust, J., Bero, L., Hill, S., Glasziou, P. (2013). Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States. PLoS Medicine, 10(8), 1-12. [More Information]
  • Krauth, D., Woodruff, T., Bero, L. (2013). Instruments for Assessing Risk of Bias and Other Methodological Criteria of Published Animal Studies: A Systematic Review. Environmental Health Perspectives, 121(9), 985-992. [More Information]
  • Grundy, Q., Bero, L., Malone, R. (2013). Interactions between Non-Physician Clinicians and Industry: A Systematic Review. PLoS Medicine, 10(11), 1-13. [More Information]
  • Nguyen, N., Bero, L. (2013). Medicaid Drug Selection Committees and Inadequate Management of Conflicts of Interest. JAMA Internal Medicine, 173(5), 338-343. [More Information]
  • Conway, J., Bero, L., Ondari, C., Wasan, K. (2013). Review of the Quality of Pediatric Medications in Developing Countries. Journal of Pharmaceutical Sciences, 102(5), 1419-1433. [More Information]
  • Schroll, J., Bero, L., Gøtzsche, P. (2013). Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ, 346(7913), 1-11. [More Information]
  • Wolfe, N., Gøtzsche, P., Bero, L. (2013). Strategies for obtaining unpublished drug trial data: a qualitative interview study. Systematic Reviews, 2, 1-11. [More Information]
  • Odierna, D., Forsyth, S., White, J., Bero, L. (2013). The Cycle of Bias in Health Research: A Framework and Toolbox for Critical Appraisal Training. Accountability in Research: policies and quality assurance, 20(2), 127-141. [More Information]
  • Pande, S., Hiller, J., Nkansah, N., Bero, L. (2013). The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database of Systematic Reviews, 2, 1-72. [More Information]
  • Bero, L., Hill, S., Habicht, J., Mathiesen, M., Starkopf, J. (2013). The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. Journal of Clinical Epidemiology, 66(2), 132-139. [More Information]
  • Bero, L. (2013). Tobacco industry manipulation of research. In David Gee, Philippe Grandjean, Steffen Foss Hansen, Sybille van den Hove, et al (Eds.), Late lessons from early warnings: science, precaution, innovation, (pp. 151-178). Copenhagen: European Environmental Agency.

2012

  • Bero, L. (2012). Assessing Risk of Bias. Australian Pharmaceutical Benefits Advisory Committee's April Meeting.
  • Norris, S., Burda, B., Holmer, H., Ogden, L., Fu, R., Bero, L., Schünemann, H., Deyo, R. (2012). Author’s specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. Journal of Clinical Epidemiology, 65(7), 725-733. [More Information]
  • Anson, A., Ramay, B., de Esparza, A., Bero, L. (2012). Availability, prices and affordability of the World Health Organization’s essential medicines for children in Guatemala. Globalization and Health, 8, 1-10. [More Information]
  • Taba, P., Rosenthal, M., Habicht, J., Tarien, H., Mathiesen, M., Hill, S., Bero, L. (2012). Barriers and facilitators to the implementation of clinical practice guidelines: A cross-sectional survey among physicians in Estonia. BMC Health Services Research, 12(1), 1-7. [More Information]
  • Hart, B., Lundh, A., Bero, L. (2012). Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ, 344(7838), 1-11. [More Information]
  • Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O., Bero, L. (2012). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 12(2012), 1-88. [More Information]
  • Hill, S., Yang, A., Bero, L. (2012). Priority Medicines for Maternal and Child Health: A Global Survey of National Essential Medicines Lists. PloS One, 7(5), 1-6. [More Information]
  • Roseman, M., Turner, E., Lexchin, J., Coyne, J., Bero, L., Thombs, B. (2012). Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ, 345, 1-10. [More Information]
  • Bero, L. (2012). Selective outcome reporting: Impact on Drug Evaluation. Australian Pharmaceutical Benefits Advisory Committee's April Meeting.
  • Malone, R., Grundy, Q., Bero, L. (2012). Tobacco industry denormalisation as a tobacco control intervention: a review. Tobacco Control, 21(2), 162-170. [More Information]

2011

  • Woodruff, T., Sutton, P., Cogliano, V., Guyton, K., Quint, J., Zeise, L., Balk, J., Bero, L., Conry, J., Fox, D., et al (2011). An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences. Health Affairs, 30(5), 931-937. [More Information]
  • Millar, T., Wong, S., Odierna, D., Bero, L. (2011). Applying the Essential Medicines Concept to US Preferred Drug Lists. American Journal of Public Health, 101(8), 1444-1448. [More Information]
  • Walleser, S., Hill, S., Bero, L. (2011). Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. Journal of Clinical Epidemiology, 64(12), 1331-1340. [More Information]
  • Dhruva, S., Bero, L., Redberg, R. (2011). Gender Bias in Studies for Food and Drug Administration Premarket Approval of Cardiovascular Devices. Circulation. Cardiovascular Quality and Outcomes, 4(2), 165-171. [More Information]
  • Bero, L. (2011). Ghosts, guests and other distortions of authorship in medical and scientific journals. COPE (Committee on Publication Ethics) North American Seminar and Forum, San Diego, North America.
  • Chen, C., Dhruva, S., Bero, L., Redberg, R. (2011). Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies. Archives of Internal Medicine, 171(6), 534-539. [More Information]
  • Krleža-Jeriç, K., Lemmens, T., Reveiz, L., Cuervo, L., Bero, L. (2011). Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Revista Panamericana de Salud Publica-Pan (American Journal of Public Health), 30(1), 87-96.
  • Roseman, M., Milette, K., Bero, L., Coyne, J., Lexchin, J., Turner, E., Thombs, B. (2011). Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA: The Journal of the American Medical Association, 305(10), 1008-1017. [More Information]
  • Bero, L. (2011). The Cochrane Collaboration and Clinical Practice Guidelines. Estonian Health Insurance Fund and World Health Organization. Tallin, Estonia (September 7).
  • Van den Ham, R., Bero, L., Laing, R. (2011). The world medicines situation report 2011: Selection of Essential Medicines, WHO/EMP/MIE/2011.2.8, (pp. 1 - 18). Geneva, Switzerland: World Health Organisation.

2010

  • White, J., Bero, L. (2010). Corporate manipulation of research: Strategies are similar across five industries. Stanford Law and Policy Review, 21(1), 105-134.
  • Smith, M., Bero, L., Carber, L. (2010). Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors. Chiropractic and Osteopathy, 18(2010), 1-8. [More Information]
  • Nkansah, N., Mostovetsky, O., Yu, C., Chheng, T., Beney, J., Bond, C., Bero, L. (2010). Effect of outpatient pharmacists’ non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database of Systematic Reviews, 7(2010). [More Information]
  • Bero, L. (2010). Evidence: Can we Trust it? Evidence on trial: has it made an impact on health?.
  • Ridge, A., Bero, L., Hill, S. (2010). Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: A case study in Zambia. BMC Health Services Research, 10, 1-9. [More Information]
  • Bero, L. (2010). International ethical guidelines regarding inclusion of children in clinical trials. StaR Child Health Conference.
  • Robertson, J., Walkom, E., Moynihan, R., Bero, L., Henry, D. (2010). Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. International Journal of Pharmacy Practice, 18(2), 88-92. [More Information]
  • Bero, L. (2010). Taming the beast: managing conflicts of interest in research. World Health Organisation Conference.
  • Montini, T., George, A., Martin-Mollard, M., Bero, L. (2010). The role of public participation in public health initiatives: An analysis of the WHO Framework Convention on Tobacco Control. Global Public Health, 5(1), 48-61. [More Information]
  • Bero, L., Carson, B., Moller, H., Hill, S. (2010). To give is better than to receive: compliance with WHO guidelines for drug donations during 2000–2008. Bulletin of the World Health Organization, 88(12), 922-929. [More Information]
  • Cataldo, J., Bero, L., Malone, R. (2010). ‘‘A delicate diplomatic situation’’: tobacco industry efforts to gain control of the Framingham Study. Journal of Clinical Epidemiology, 63(8), 841-853. [More Information]

2009

  • Rasmussen, N., Lee, K., Bero, L. (2009). Association of trial registration with the results and conclusions of published trials of new oncology drugs. 6th International Congress on Peer Review and Biomedical Publication 2009, Vancouver, British Columbia, Canada. [More Information]
  • Apollonio, D., Bero, L. (2009). Evidence and argument in policymaking: development of workplace smoking legislation. BMC Public Health, 9, 1-10. [More Information]
  • Rattinger, G., Bero, L. (2009). Factors Associated with Results and Conclusions of Trials of Thiazolidinediones. PloS One, 4(6), 1-10. [More Information]
  • Cook, D., Boyd, E., Grossman, C., Bero, L. (2009). Journalists and conflicts of interest in science: Beliefs and practices. Ethics in Science and Environmental Politics, 9(1), 33-40. [More Information]
  • Robertson, J., Moynihan, R., Walkom, E., Bero, L., Henry, D. (2009). Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals. PLoS Medicine, 6(11), 1-5. [More Information]
  • White, J., Bandura, A., Bero, L. (2009). Moral disengagement in the corporate world. Accountability in Research: policies and quality assurance, 16(1), 41-74. [More Information]
  • Vedula, S., Bero, L., Scherer, R., Dickersin, K. (2009). Outcome Reporting in Industry-Sponsored Trials Of Gabapentin for Off-Label Use. The New England Journal of Medicine, 361(20), 1963-1971. [More Information]
  • Kummerfeldt, C., Barnoya, J., Bero, L. (2009). Philip Morris involvement in the development of an air quality laboratory in El Salvador. Tobacco Control, 18(3), 241-244. [More Information]
  • Nkansah, N., Nguyen, T., Iraninezhad, H., Bero, L. (2009). Randomized trials assessing calcium supplementation in healthy children: Relationship between industry sponsorship and study outcomes. Public Health Nutrition, 12(10), 1931-1937. [More Information]
  • Cook, D., Gurugubelli, R., Bero, L. (2009). Risk Management Policy and Black-Box Warnings: A Qualitative Analysis of US FDA Proceedings. Drug Safety, 32(11), 1057-1066. [More Information]
  • Dhruva, S., Bero, L., Redberg, R. (2009). Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices. JAMA: The Journal of the American Medical Association, 302(24), 2679-2685. [More Information]
  • Odierna, D., Bero, L. (2009). Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. Journal of Clinical Epidemiology, 62(12), 1268-1278. [More Information]
  • Bero, L. (2009). Tainted evidence on drugs. International Cochrane Symposium. Evidence-based Medicine and Systematic Reviews: Challenges and Opportunities.
  • Cook, D., Bero, L. (2009). The Politics of Smoking in Federal Buildings: An Executive Order Case Study. American Journal of Public Health, 99(9), 1588-1595. [More Information]

For support on your academic profile contact .